The prospective study demonstrated that patients received better care for acute coronary syndrome, including fewer days in the hospital and more medically appropriate use of medication, when the ACSETS critical care pathway was used.
Within the first 24 hours after arrival in the emergency department, at discharge and during 12 months following discharge, more ACSETS patients than pre-ACSETS patients received all eight guideline-based acute coronary syndrome treatment medications studied.
At discharge, ACSETS patients had their medications reviewed so that the appropriate drug therapies were prescribed.
While the study showed no difference in in-patient mortality rates among the two groups, it did show that the ACSETS patients admitted for heart attack had a mortality rate of 19 percent less than the control group for up to one year after discharge.
After discharge, higher refill rates were seen for the ACSETS group than for the pre-ACSETS group, with that difference showing statistical significance for clopidogrel and statins," Cziraky said.
Physicians and other medical staff members were trained on the ACSETS order sheets for a period over 26 weeks before the study began.
ACSETS is used for the treatment of acute coronary syndrome patients with unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI).